Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Chronic kidney disease (CKD) is a public health concern in China. Despite its heavy health and socioeconomic burden, early detection rate remains low. Point-of-care testing (POCT) for albuminuria using urine dipsticks represents a practical screening approach, promising to raise public awareness of kidney health and improve early detection rate. This study aims to evaluate the cost-effectiveness of Point-of-care (POC) albuminuria testing in China.
We constructed and validated a microsimulation model for a hypothetical cohort of 100,000 individuals aged 45 years and older over a 50-year horizon among both the general population and adults with diabetes. Screening strategies included annual usual care only (no screening) and POC albuminuria testing conducted every 1, 2, 5, or 10 years, or once in a lifetime. Model parameters were obtained from the published literature and existing data sources in China. In the model, we evaluated incremental cost-effectiveness ratios (ICERs) and health outcomes of POC albuminuria testing—including life years gained and decrease in cardiovascular disease (CVD) and kidney failure requiring replacement therapy (KFRT) events compared with usual care from a societal perspective.
Compared with usual care, POC albuminuria testing was generally cost-effective at a willingness-to-pay (WTP) threshold of $40,119 (three times China’s gross domestic product per capita). The ICERs ranged from $9432 to $26,735 per quality-adjusted life year (QALY) among adults with diabetes, and from $11,194 to $42,157 per QALY among general population. Among all strategies evaluated, annual POC albuminuria testing initiated at age 45 years yielded the best cost-effectiveness. With respect to health outcomes, annual POC screening from age 45 years yielded incremental gains of 0.193 and 0.262 life-years in the general population and adults with diabetes, respectively, and prevented 37 and 18 cases of CVD per 1,000 individuals, as well as 13 and 70 cases of KFRT per 10,000 individuals.
POC albuminuria testing was cost-effective compared with usual care in the Chinese population. Annual screening starting at age 45 years was considered the most cost-effective, contributing to better health outcomes and providing scientific evidence for developing national strategies for CKD prevention and intervention.
